Skip to main
COYA
COYA logo

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is in a strong financial position, having strengthened its cash reserves via private placements and strategic investments, which will support key clinical milestones anticipated in 2025. Despite a widening net loss, the company's increased research and development expenses signal a commitment to advancing its innovative multi-modality Treg therapies, particularly in neurodegenerative and autoimmune diseases. Furthermore, the partnership with Reddy underscores the confidence in Coya's differentiated approach, which may lead to transformative advancements in ALS treatment and overall shareholder value in the future.

Bears say

Coya Therapeutics faces significant challenges in the highly competitive landscape of amyotrophic lateral sclerosis (ALS) drug development, where past failures highlight difficulties due to the disease's heterogeneity and ineffective clinical trial designs. Despite its innovative multi-modality approach aimed at enhancing Treg function to address inflammation and immune regulation, the historical setbacks of similar therapies underscore the risks associated with single-mechanism treatments in broader patient populations. Consequently, the combination of these factors raises concerns about the viability and effectiveness of Coya's therapeutic strategy in a market that has seen high-profile failures.

COYA has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 7 analysts, COYA has a Strong Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.